Management of difficult-to-treat inhibitor patients.
The workshop looked at seven scenarios based on fictional and real-life cases of difficult-to-treat patients with haemophilia A or haemophilia B and inhibitors with the aim of sharing clinical opinion and experience from around the world. Delegate opinions on the best treatment option for each scenario are described together with actual treatment given in real-life cases and its outcome.
Giangrande
P L F
PL
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK. paul.giangrande@ndm.ox.ac.uk
Escobar
M A
MA
D000293:Adolescent; D000328:Adult; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D055815:Young Adult
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa